Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody

A method for treating an HLA-G expressing cancer in a subject comprising administering to the subject an effective amount of an anti-HLA-G/anti-CD3 antibody and an effective amount of an anti-PD1/anti-LAG3 bispecific antibody, wherein the anti-PD1/anti-LAG3 bispecific antibody comprises a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising

• (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1,
• (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and
• (iii) CDR-H3 comprising an amino acid sequence of SEQ ID NO:3;
• and
• a VL domain comprising
• (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4;
• (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and
• (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.

A combination comprising an anti-PD1/anti-LAG3 bispecific antibody and an anti-HLA-G/anti-CD3 bispecific antibody, wherein the anti-PD1/anti-LAG3 bispecific antibody comprises a first antigen binding domain that specifically binds to programmed cell death protein 1 (PD1) and a second antigen binding domain that specifically binds to Lymphocyte activation gene-3 (LAG3), wherein the first antigen binding domain specifically binding to PD1 comprises a VH domain comprising

• (i) CDR-H1 comprising the amino acid sequence of SEQ ID NO:1,
• (ii) CDR-H2 comprising the amino acid sequence of SEQ ID NO:2, and
• (iii) CDR-H3 comprising the amino acid sequence of SEQ ID NO:3;
• and
• a VL domain comprising
• (i) CDR-L1 comprising the amino acid sequence of SEQ ID NO:4;
• (ii) CDR-L2 comprising the amino acid sequence of SEQ ID NO:5, and
• (iii) CDR-L3 comprising the amino acid sequence of SEQ ID NO:6.